Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 3, 2013, Pages 314-325

  Hasei, Joe ^a   Sasaki, Tsuyoshi ^a   Tazawa, Hiroshi ^a,b   Osaki, Shuhei ^a   Yamakawa, Yasuaki ^a   Kunisada, Toshiyuki ^a   Yoshida, Aki ^a   Hashimoto, Yuuri ^a   Onishi, Teppei ^a   Uno, Futoshi ^a   Kagawa, Shunsuke ^a   Urata, Yasuo ^c   Ozaki, Toshifumi ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONTUSUGENE LADENOVEC; E1A PROTEIN; MICRORNA; OBP 301; OBP 702; ONCOLYTIC ADENOVIRUS; PROTEIN P21; PROTEIN P53; TELOMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TRANSACTIVATION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; UPREGULATION;

ADENOVIRIDAE; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OSTEOSARCOMA; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874880655     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0869     Document Type: Article

References (50)

1. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res 2009;152: 15-32.
2. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007;459: 40-7.
3. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al. Improvement in histologic response but not survival in osteosarcomapatients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99: 112-28.
4. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106: 1154-61.
5. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62: 10-29.
7. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res 2012;730: 90-7.
8. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010;31: 9-18.
9. Umehara N, Ozaki T, Sugihara S, Kunisada T, Morimoto Y, Kawai A, et al. Influence of telomerase activity on bone and soft tissue tumors. J Cancer Res Clin Oncol 2004;130: 411-6.
10. Aogi K, Woodman A, Urquidi V, Mangham DC, Tarin D, Goodison S. Telomerase activity in soft-tissue and bone sarcomas. Clin Cancer Res 2000;6: 4776-81.
11. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18: 65-8.
12. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10: 285-92.
13. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010;18: 429-34.
14. Sasaki T, Tazawa H, Hasei J, Kunisada T, Yoshida A, Hashimoto Y, et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res 2011;17: 1828-38.
15. Li G, Kawashima H, Ogose A, Ariizumi T, Xu Y, Hotta T, et al. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. J Cancer Res Clin Oncol 2011;137: 1037-51.
16. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137: 413-31.
17. Fujiwara K, Daido S, Yamamoto A, Kobayashi R, Yokoyama T, Aoki H, et al. Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J Biol Chem 2008;283: 388-97.
18. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997;14: 929-35.
19. Blagosklonny MV, el-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 1996;67: 386-92.
20. Zeng Y, Prabhu N, Meng R, Eldeiry W. Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int J Oncol 1997;11: 221-6.
21. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16: 2221-32.
22. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced nonsmall- cell lung cancer. J Natl Cancer Inst 1999;91: 763-71.
23. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006;97: 554-61.
24. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24: 1689-99.
25. Sakai R, Kagawa S, Yamasaki Y, Kojima T, Uno F, Hashimoto Y, et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther 2010;9: 1884-93.
26. Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, et al. A novel apoptotic mechanism of genetically engineered adenovirus- mediated tumour-specific p53 overexpression through E1Adependent p21 and MDM2 suppression. Eur J Cancer 2012;48: 2282-91.
27. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008;99: 385-90.
28. Bagchi S, Raychaudhuri P, Nevins Jr. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 1990;62: 659-69.
29. Emmrich S, Putzer BM. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 2010;9: 2555-67.
30. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008;68: 8191-4.
31. Tazawa H, Yano S, Yoshida R, Yamasaki Y, Sasaki T, Hashimoto Y, et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer 2012;131: 2939-50.
32. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006;126: 121-34.
33. Liu TC, Galanis E,Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4: 101-17.
34. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62: 6165-71.
35. Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, et al. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res 2009;15: 3725-32.
36. Chattopadhyay D, Ghosh MK, Mal A, Harter ML. Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol 2001;75: 9844-56.
37. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009;9: 738-48.
38. WuX, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A 1994;91: 3602-6.
39. Itoshima T, Fujiwara T, Waku T, Shao J, Kataoka M, Yarbrough WG, et al. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res 2000;6: 2851-9.
40. Tian X, Chen Y, Hu W, Wu M. E2F1 inhibits MDM2 expression in a p53- dependent manner. Cell Signal 2011;23: 193-200.
41. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A 2012;109: 5316-21.
42. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res 2011;71: 7071-9.
43. Salvatori L, Caporuscio F, Coroniti G, Starace G, Frati L, Russo MA, et al. Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol 2009;220: 35-44.
44. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007;6: 3263-70.
45. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15: 3451-61.
46. Ternovoi VV, Curiel DT, Smith BF, Siegal GP. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab Invest 2006;86: 748-66.
47. Hellwinkel OJ, Muller J, Pollmann A, Kabisch H. Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J Gene Med 2005;7: 407-19.
48. Ganjavi H, Gee M, Narendran A, Parkinson N, Krishnamoorthy M, Freedman MH, et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 2006;13: 415-9.
49. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, et al. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 2008;68: 7966-74.
50. Su C, Cao H, Tan S, Huang Y, Jia X, Jiang L, et al. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci 2008;106: 242-50.